Inorganic phosphate (P i ) is an essential nutrient for living organisms. It plays a key role in diverse physiological functions, including osteoblast differentiation and skeletal mineralization. Relevantly, P i is emerging as an important signaling molecule capable of modulating multiple cellular functions by altering signal transduction pathways, gene expression, and protein abundance in many cell types. To our knowledge, the consequences of elevated P i on behavior of breast cancer cells have been poorly addressed. In this study we investigate the effects of P i on proliferation of MDA-MB-231 breast cancer cells. We report that P i inhibits proliferation of MDA-MB-231 cells by slowing cell cycle progression, without apoptosis occurrence. We found that P i causes cells to accumulate in G1 phase in a time-dependent manner. Accordingly, G1 accumulation was associated with a decrease of cyclin A and cyclin E and an increase of cell cycle inhibitors p21 and p27 protein levels, respectively. Moreover, the P iinduced antiproliferative effect was dynamically accompanied by profound changes in ERK1/2 and STAT3 protein and phosphorylation levels in response to P i . Altogether, our data represent the first evidence of P i acting as a novel signaling molecule in MDA-MB-231 breast cancer cells, capable of eliciting a strong antiproliferative action and suggest that targeting P i levels at local sites might represent the rationale for developing novel strategies for therapeutic intervention in triple-negative breast cancer.
Introduction

I
norganic phosphate (P i ) is an essential nutrient for living organisms. It plays a key role in diverse physiological functions, including osteoblast differentiation and skeletal mineralization. 1 Serum P i level is maintained within a narrow range through a complex interplay between intestinal absorption, exchange with intracellular and bone storage pools, and renal tubular reabsorption and depends mainly on the activity of Na/P i cotransporters.
2 P i is abundant in the diet, and intestinal absorption of P i is efficient and minimally regulated. The kidney is a major regulator of P i homeostasis and can increase or decrease its P i reabsorptive capacity to accommodate P i need. Adequate control of P i homeostasis is crucial because a moderate increase in serum P i concentration and polymorphisms in genes involved in P i metabolism may result in bone impairment and influence the aging process and lifespan. 3 The amount of P i in the human diet, and in particular the Western diet, continues to increase. 4, 5 In addition, new drug delivery systems containing calcium phosphate nanoparticles have been developed. Notably, release of P i from hydroxyapatite nanoparticles and its retention at local sites are known to occur, thus affecting P i concentrations locally. 6 Thus, it will be important to fully understand the influence of P i on cell function and the possible relationship to cancer. 7, 8 Relevantly, P i is emerging as an important signaling molecule capable of modulating multiple cellular functions by altering signal transduction pathways, gene expression, and protein abundance in many cell types. 9 Previously, we showed that P i inhibits proliferation and aggressiveness of human osteosarcoma U2OS cells, identifying adenylate cyclase, beta3 integrin, Rap1, and ERK1/2 as proteins whose expression and function are relevantly affected by P i . 10, 11 In addition, more recently, we demonstrated that P i is capable of inducing sensitization of osteosarcoma cells to doxorubicin in a p53-dependent manner and through a mechanism involving ERK1/2 down-regulation.
Materials and Methods
Materials
All cell culture materials were from Gibco-Life Technologies (Gaithersburg, MD). Anti-tubulin antibodies were obtained from Oncogene-Calbiochem (La Jolla, CA). Anti-p-ERK antibodies were obtained from Cell Signaling Technology (Danvers, MA). All other antibodies were obtained from Santa Cruz Biotechnology (San Diego, CA).
Cell culture and treatments
The MDA-MB-231 human breast cancer cell line was obtained from the American Type Culture Collection (Rockville, MD). MDA-MB-231 cells were grown in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, and 10% fetal bovine serum and cultured at 37°C in a 5% CO 2 humidified atmosphere. Typically, cells were split (5 · 10 5 /10-cm plate) and grown in 10% serum containing medium. After 24 h, the medium was removed, cells were washed with phosphate-buffered saline (PBS) and cultured again in 10% serum fresh medium supplemented or not (control) with P i (time 0).
The control medium contained 0.916 mM P i , and P i concentrations listed in the figures are the final P i medium concentrations. Added P i was in the form of NaPO 4 , pH 7.4, from Sigma. [10] [11] [12] [13] Floating cells were recovered from culture medium by centrifugation, and adherent cells were harvested by trypsinization. Both floating and adherent cells were used in experiments aimed to study expression of proteins involved in apoptosis and to perform FACS analysis. 14 
Cell viability assay
Viable cells were determined by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay, as previously described. 14, 15 Briefly, cells were seeded in 96-multiwell plates at the density of 4 · 10 3 cells/well and grown in 10% serum containing medium. After 24 h, the medium was removed, and cells were washed with PBS and cultured again in 10% serum fresh medium supplemented or not (control) with P i (time 0) for up to 72 h (see the figure legends). Before harvesting, 100 lL of MTT solution (5 mg/mL) was added to each well and incubated at 37°C for 3 h, then the formazan product was solubilized by the addition of 100 lL of 0.04 normality (N) HCl isopropanol. The optical density of each sample was determined by measuring the absorbance at 570 nm versus 650 nm using an enzyme-linked immunosorbent assay reader (Molecular Devices, Downingtown, PA). Cell proliferation assays were performed three times (in replicates of six wells for each data point in each experiment). Data are presented as means -standard deviation for a representative experiment.
Evaluation of cell cycle phases by flow cytometry
After P i treatment, cells were recovered as described in Cell culture and treatments, fixed by resuspension in 70% ice-cold methanol/PBS, and incubated overnight at 4°C. After fixing, samples were pelleted at 400 g for 5 min, and pellets were washed once with ice-cold PBS and centrifuged for a further 5 min. Pellets were resuspended in 0.5 mL of DNA staining solution (50 lg/mL of propidium iodide [PI] and 100 lg of RNase A in PBS), and incubated at 37°C for 1 h in the dark. Samples were transferred to 5-mL Falcon tubes and stored on ice until assayed. Flow cytometric analysis was performed using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA) interfaced with a Hewlett-Packard computer (mod. 310) for data analysis performed with the ModiFIT Cell Cycle Analysis software. For the evaluation of intracellular DNA contents, at least 20,000 events for each point were analyzed, and regions were set up to acquire quantitative data of cells that fell into the normal G1, S, and G2 regions and with fragmented DNA (sub-G1 or apoptotic events).
12,14
Preparation of cell lysates
Cell extracts were prepared as follows. Briefly, three to five volumes of RIPA buffer (PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing 10 lg/mL aprotinin, leupeptin, and 1 mM phenylmethylsulfonyl fluoride were added to recovered cells. After incubation on ice for 1 h, samples were centrifuged at 18,000 g in an Eppendorf microcentrifuge for 15 min at 4°C and the supernatant (SDS total extract) was recovered. Some aliquots were taken for protein quantification according to Bradford method (Bradford, 1976); others were diluted in 4 · Laemmli buffer, boiled, and stored as samples for immunoblotting analysis. 16 
Immunodetection of proteins
Typically, we employed 20-40 lg of total extracts for immunoblotting. Proteins from cell preparations were separated by SDS-PAGE and transferred onto nitrocellulose sheets (Schleicher & Schuell, Dassel, Germany) by a Mini TransBlot apparatus BioRad (Hercules, CA). II Goat anti-rabbit or anti-mouse antibodies, conjugated with horseradish peroxidase (BioRad), were used as a detection system (ECL) according to the manufacturer's instructions (Amersham Biosciences, Amersham, United Kingdom). 17 
Statistical analysis
Experiments were performed three times with replicate samples, except where otherwise indicated. Data are plotted as mean -SD (standard deviation). The means were compared using analysis of variance (ANOVA) plus Bonferroni's t-test; p values of less than 0.05 were considered significant. National Institutes of Health Image J 1.42Q (NIH, Bethesda, MD) software was used for densitometric analysis.
Results
P i inhibits proliferation of human MDA-MB-231 breast cancer cells
The triple-negative human breast cancer cell line MDA-MB-231 is a well-established and widely used model system of highly aggressive breast cancer cells. 18, 19 To evaluate the consequences of elevated P i on behavior of breast cancer cells, first we looked at the impact of P i on proliferation of MDA-MB-231 cells. To this purpose, first we performed dose-response experiments. Throughout our experiments, we used a spectrum of final concentration of P i in agreement with most of the published studies on P i -triggered effects.
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MDA-MB-231 cells were incubated with increasing (2.5, 5, and 10 mM) concentrations of P i for 72 h, and then cell proliferation was determined by conventional MTT assay and by direct cell number counting. Figure 1A shows that P i causes a statistically significant reduction of cell viability ( p < 0.05) in a dose-dependent manner of 12%, 35%, and 40% at 2.5, 5, and 10 mM concentrations, respectively.
Next, we performed time-course experiments. MDA-MB-231 cells were exposed to 5 mM P i (submaximal dose) for up to 72 h, after which cell proliferation was determined by conventional MTT assay and by direct cell number counting. Figure 1B , shows that P i caused a statistically significant reduction of cell viability ( p < 0.05) of 12%, 26%, and 40% at 24, 48, and 72 h, respectively.
Parallel direct cell counting and growth curves yielded similar results (Fig. 1C) .
The antiproliferative effect induced by P i in MDA-MB-231 cells is paralleled by consistent changes of relevant cell cycle regulating protein levels
To extend data on the antiproliferative effect of P i in MDA-MB-231 cells, we studied the expression of some relevant cell cycle regulating proteins.
To this purpose, MDA-MB-231 cells were exposed to 5 mM P i for 24, 48, and 72 h, after which cell extracts were prepared and Western blotting was used to examine the levels of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1, and of cyclin A and cyclin E proteins.
20,21 Figure 2 shows that at each time point considered (from 24 h up to 72 h) in P i -treated cells the amount of the positive growth regulators cyclin A and E was decreased compared to untreated control cells, whereas the amount of p21 and p27 cell growth inhibitors was increased. These variations were clearly evident at 48 h and very strong at 72 h of P i treatment.
P i causes slowing of the cell division cycle but not apoptosis occurrence in MDA-MB-231 cells
To further explore the inhibitory growth effect of P i on MDA-MB-231 cells, the distribution of cells in cell cycle phases was evaluated by flow cytometric analysis of PIstained cells in response to P i . We also looked at the proportion of cells with hypoploid DNA content (sub-G1 population), characteristic of cells having undergone DNA fragmentation, which is a biochemical hallmark of apoptosis. Figure 3 shows that at each time point considered (from 24 h up to 72 h) in P i -treated MDA-MB-231 cells the percentage of G1 phase cells was significantly higher than that of control untreated cells, with a concomitant decrease of S phase. Moreover, no obvious appearance of sub-G1 population in response to P i was observed up to 72 h.
Interestingly, as shown in Fig. 3B , in contrast to MDA-MB-231 cells, no obvious changes on cell cycle distribution in response to P i could be seen in MCF-7 breast cancer cells, which are not ''triple negative'' and express estrogen and progesterone receptors. This strongly suggests that P i can have discrete effects on cell cycle depending on cell type or cellular background.
P i relevantly affects ERK1/2 and STAT3 protein and phosphorylation levels
The extracellular-signal-regulated kinase (ERK)-dependent and signal transducer and activator of transcription 3 (STAT3)-dependent signaling pathways are relevant to breast cancer, and several studies demonstrate they are frequently activated. 22, 23 In order to investigate the possible role of ERK1/2 and STAT3 in the antiproliferative effect of P i in MDA-MB-231 cells, Western blotting was used to examine the expression and phosphorylation (activation) of ERK1/2 and STAT3 from extracts of cells treated with 5 mM P i during a time course from 1 h up to 24 h (to look at ''early'' events) and for 24, 48, and 72 h (to look at ''late'' events). Figure 4 shows that P i induced an early and transient increase in ERK activity at 1 h, rapidly declining after 2-6 h of P i incubation (Fig. 4A) , followed by a strong inhibition starting at 24 h and maintained for up to 72 h of P i treatment (Fig.  4A, 4B) . No obvious variations in the total amount of ERK1/2 protein levels occurred at any time points.
As far as STAT3 was concerned, Fig. 4 shows that P i induced a small increase at 1 and 2 h and a more evident decrease of STAT3 phosphorylation at 6 and 24 h of treatment, respectively (Fig. 4A) , and, very surprisingly, a dramatic decrease of the total amount of STAT3 protein with a strong increase of its phosphorylation at 48 and 72 h of P i treatment (Fig. 4B ).
Discussion
Currently, there is no effective therapy for triple-negative breast cancer, and new pharmacological approaches for affected patients are warranted. 24, 25 In this study we report that in MDA-MB-231 human breast cancer cell line, a well-established model system of highly aggressive triple-negative breast cancer, P i strongly inhibits proliferation.
Dietary supplements, phytotherapeutic agents, and naturally occurring molecules with antitumor activity and with the least toxicity to normal tissues are suggested as possible candidates to be investigated alone and/or for their synergistic efficacy in combination with antineoplastic drugs 22, [26] [27] [28] [29] [30] In particular, diet represents an environmental factor that can be easily manipulated and has a profound effects on functional genomics and proteomics; its potential relationship with cancer is well known.
31,32 P i is a common dietary component that may directly alter cell behavior in such a manner. transduction pathways, gene expression, and protein abundance in many cell types. 9 Additionally, P i has been shown to stimulate specific signal transduction pathways, including ERK1/2 and Akt, and to increase cell proliferation in some cell types, such as preosteoblastic MC3T3-E1 cells, human lung cells, and epidermal JB6 cells, thereby defining P i as a novel mitogenic signal for such cells. 13, 34, [37] [38] [39] [40] [41] Notably, the proliferative effect of P i is not a widespread phenomenon affecting all cell types.
Previously, we showed that P i inhibits proliferation and aggressiveness of human osteosarcoma U2OS cells, identifying adenylate cyclase, beta3 integrin, Rap1, and ERK1/2 as proteins whose expression and function are relevantly affected by P i . 10, 11 In addition, more recently, we demonstrated that P i is capable of inducing sensitization of osteosarcoma cells to doxorubicin in a p53-dependent manner and through a mechanism involving Erk1/2 down-regulation. 12 Moreover, apoptosis induction in response to P i has been reported in MO6-G3 odontoblast-like cells. 42 So far, little research has been directed at determining the consequences of elevated P i on the behavior of breast cancer cells. 43, 44 In this study, we describe the first evidence of P i acting as a novel signaling molecule capable of eliciting a strong antiproliferative action in triple-negative MDA-MB-231 breast cancer cells. We report that P i inhibits proliferation of MDA-MB-231 cells by slowing cell cycle progression, without apoptosis occurrence. We show that P i time dependently causes the cells to accumulate in G1 phase. Accordingly, G1 accumulation of MDA-MB-231 cells is associated with a decrease of cell cycle positive effectors cyclin A and cyclin E and an increase of cell cycle inhibitors p21 and p27 protein levels, respectively.
Interestingly, in contrast to MDA-MB-231 cells, the antiproliferative effects of P i do not occur in MCF-7 breast cancer cells, which are not ''triple negative'' and express estrogen and progesterone receptors, without obvious changes in cell cycle distribution in response to P i . This strongly suggests that P i can have discrete effects on cell proliferation depending on cell type and cellular background.
Initial analysis of the underlying molecular mechanisms indicates that the P i -induced antiproliferative effect in MDA-MB-231 cells is dynamically accompanied by profound changes in phosphorylation status and protein levels of ERK1/2 and STAT3 in response to P i . The Ras/Raf/Erk signaling pathway is relevant to breast cancer and is frequently activated, and its importance in the control of proliferation is largely known. [45] [46] [47] A blockade of such signaling pathway is considered a relevant strategy for therapeutic intervention. 48, 49 Importantly, we found that P i treatment results in a prolonged inhibition of ERK1/2 phosphorylation (without significant change in the total amount of ERK1/2 protein). On the other hand, multiple lines of evidence place STAT3 at a central node in the development, progression, and maintenance of many human tumors, including breast cancer, and STAT3 has been validated as an anticancer target in several contexts. [50] [51] [52] Importantly, we found that exposure of MDA-MB-231 cells to P i resulted in inhibition of phosphorylation of STAT3 (at 6-24 h of treatment), and then in a strong decrease of STAT3 protein abundance with an increase of its phosphorylation as a late effect (at 48-72 h of treatment).
Our data suggest that P i strongly inhibits proliferation of MDA-MB-231 cells, possibly through inhibition of ERK1/2 and STAT3 signaling pathways within the tumor cells themselves. The detailed molecular mechanism underlying this growth inhibition by P i is just starting to be understood, and interplay between these pathways (and possibly others) is very likely implicated in the observed slowing of cell cycle progression of MDA-MB-231 cells. However, we do know that further studies and more exhaustive experiments are warranted.
Combination chemotherapy has received more attention to find compounds that could increase the therapeutic index of clinical anticancer drugs. 53 P i is an attractive candidate for investigation.
New drug delivery systems containing calcium phosphate nanoparticles have been developed. Very interestingly, release of P i from hydroxyapatite nanoparticles and its retention at local sites are known to occur, thus affecting P i concentrations locally. 6 Collectively, our data represent the first evidence of P i as a signaling molecule in MDA-MB-231 breast cancer cells and indicate that P i may act as a potent growth suppressor by slowing cell cycle progression, possibly via ERK1/2 and STAT3 inhibition. These findings suggest that targeting P i levels at local sites could contribute to the development of novel strategies for therapeutic intervention in triple-negative breast cancer.
